Variable category | Side effect developed | |||
---|---|---|---|---|
Yes | No | X2 (P) | ||
n (%) | n (%) | |||
Age category in years | ≤35 | 144 (49.1) | 2 (28.6) | 2.1 (0.72) |
> 35 | 149 (51.9) | 5 (71.4) | ||
Gender | Male | 189 (64.5) | 6 (85.7) | 1.35 (0.24) |
Female | 104 (35.5) | 1 (14.3) | ||
Current substance use | Yes | 74 (25.3) | 0 (0.0) | 2.35 (0.13) |
No | 219 (74.7) | 7 (100) | ||
Total daily chlorpromazine equivalent dose of FGAs in mg | < 300 | 165 (56.3) | 4 (57.1) | 0.45 (0.8) |
300–600 | 111 (37.9) | 3 (42.9) | ||
600–1000 | 17 (5.8) | 0 (0.0) | ||
Duration of illness in years | < 1 | 17 (5.8) | 0 (0.0) | 9.98 (0.04) |
1–5 | 171 (58.4) | 6 (85.7) | ||
≥5 | 105 (35.8) | 1 (14.3) | ||
Presence of comorbidity | Yes | 31 (10.6) | 1 (14.3) | 0.1 (0.75) |
No | 262 (89.4) | 6 (85.7) | ||
Number of antipsychotics | 1 | 201 (68.6) | 6 (85.7) | 0.91 (0.34) |
≥2 | 92 (31.4) | 1 (14.3) |